We investigated immunohistochemical localization of V2 vasopressin receptor along the nephron using a specific polyclonal antibody. Staining was observed in some of thick ascending limbs and all of principal and inner medullary collecting duct (IMCD) cells. Not only basolateral but also luminal membrane was stained in collecting ducts, especially in terminal IMCD (tIMCD).
Introduction
The main role of the kidney is to maintain the body fluid homeostasis by producing concentrated and diluted urine (1) . Several hormones, i.e., arginine vasopressin (AVP),' atrial natriuretic peptide, parathyroid hormone, calcitonin, glucagon, mineralocorticoids, and glucocorticoids, are known to influence renal ion and water transport. Among these hormones, AVP is the key hormone responsible for producing concentrated urine, and it is excreted in high concentrations during antidiuresis.
At least two types of AVP receptors are known in the kidney: Vla and V2 receptors (2) . Vla receptors are localized mainly in the vascular system and glomeruli and participate in the vasopressor effect of AVP (3) . The antidiuretic action of AVP is mediated through adenylate cyclase-coupled V2 receptors, and cAMP is the second messenger for the antidiuretic action of AVP (4) . AVP-sensitive adenylate cyclase is widely distributed in the nephron: from the medullary thick ascending limbs to the collecting ducts (5) . V2 receptors are believed to be located only in the basolateral membrane. Recently, AVP has been shown to act at the luminal membrane in the cortical collecting duct (CCD), probably via luminal VIa receptors (6) . This finding gave physiological meaning to large excretions of AVP into the urine, especially in antidiuresis. The presence of VIa receptors in CCD suggests the possibility that luminal Vla or V2 receptors could exist in other nephron segments, thus indicating that there is a physiological role for the high concentrations of urinary AVP during antidiuresis (7) .
Recently, cDNAs of V2 and VIa vasopressin receptor were cloned (8, 9) . In the present study, we investigated the immunohistochemical localization of V2 vasopressin receptor along the nephron using specific polyclonal antibody. Our data showed the presence of V2 receptor both in the luminal and basolateral membrane of distal nephron, especially heavily in the terminal inner medullary collecting duct (tIMCD).
The tIMCD is the final segment of the nephron and is an important segment for urine concentration. The IMCD has V2 receptors as well as receptors for atrial natriuretic peptide (10) . Its water and urea permeabilities are quite high, especially in the presence of AVP (11) . Thus, as the second part of our study, we investigated the effects of luminal and basolateral AVP in the tIMCD on water and urea permeability and cAMP accumulation to ascertain the functional role of V2 receptors in the luminal and basolateral membrane of tIMCD.
Methods
Materials. AVP, [deamino-Cys', D-Arg8] -vasopressin (dD-AVP) (V2 agonist), [Pmp',Tyr(Et)2, Val4, Arg8]-vasopressin (PTEtV-AVP) (V2 antagonist) ( 12) , oxytocin, [Thr4, Gly7]-oxytocin (tg-OXT) (oxytocin agonist) (13) , and collagenase were obtained from Sigma Chemical Co. (St. Louis, MO). [Pmp1, Tyr(Me)2, Arg8]-vasopressin (PTMe-AVP) (Vla antagonist) ( 14) was purchased from Peptide Institute (Osaka, Japan). desGly-NH2-d(CH2)5[Tyr(Me)2, Thr41-oxyvasotocin (GN-OVT) ( Immunohistochemical study. To examine the localization of V2 receptors in the kidney, kidney slices were made. Rats were injected with pentobarbital (5 mg/100 gram body weight) and the left kidney was fixed with 4% paraformaldehyde in PBS through the abdominal aorta. Kidney was cut into the blocks of cortex, outer medulla, and inner medulla. The blocks were then fixed by immersion in 4% paraformaldehyde in PBS for 60 min, 2% paraformaldehyde, and 10% sucrose in PBS for 4 h, 15% sucrose in PBS for 4 h, and 20% sucrose in PBS for 4-6 h. All solutions were cooled on ice. The blocks were then rapidly frozen in liquid nitrogen.
4-to 5-tim thick sections were cut and mounted on eggwhite-coated slides. The sections were incubated with normal goat serum for 1 h at room temperature. After rinsing with PBS, the sections were incubated with IgG fraction of rabbit antisera (anti-N-3 peptide, 1:500) or preimmune rabbit serum (1:500) overnight at 4°C. The sections were then rinsed with PBS and incubated with FITC-conjugated goat-anti-rabbit IgG F(ab')2 (Cappel, Organon Teknika Corp., Durham, NC) for 1 h at room temperature. The sections were rinsed by PBS with vibration and sealed in a mixture of 10% PBS and 90% glycerol containing 0.3% para-phenylenediamine. The specimens were photographed with a confocal laser scanning microscope (LSM-10; Carl Zeiss Inc., Ober-V2 Arginine Vasopressin Receptor along the Nephron kochen, Germany) or with a conventional fluorescent microscope. Exactly same exposure time was used for the photographs of control and positive studies. The thickness of scanning section using confocal laser scanning microscopy < 1 im (manufacturer's data).
Isolated tubule perfusion study. Terminal IMCD was dissected from the terminal two-thirds of the inner medulla of the kidney from pathogen-free male Sprague Dawley rats weighing 50-100 grams (Japan Laboratory Animals Inc., Tokyo, Japan), as described previously (11, 20, 21) . The basic solution for the isolated tubule perfusion study (solution A) had the following composition (mM): 118 NaCl, 25 NaHCO3, 2.5 K2HPO4, 1 MgSO4, 1 Ca lactate, 2 Na acetate, 5.5 glucose, 5 L-alanine, 2 L-leucine. This solution was continuously aerated with 5% C02-95% 02-The composition of the basic solution for the cAMP accumulation study (solution B) was (mM): 130 NaCl, 5 KCl, 1 NaH2PO4, 1 MgSO4, 1 Ca lactate, 2 Na acetate, 5.5 glucose, 5 L-alanine, 2 L-leucine, 10 Hepes; and pH was adjusted to 7.4 by NaOH.
Osmotic water permeability (Pf) study. Pf was measured as described previously (11, 20, 21 ) . In brief, Pf was determined by measuring the water flux resulting from 200 mOsm/kg x H20 bath-to-lumen osmolality gradient. The perfusion and bath solutions were nearly identical to the dissection solution (solution A), the only exception being that an additional 106 mM NaCl that was added to the bath solution.
Creatinine was used as the volume marker for the measurement of Pf. Pf was calculated using the equation of Al-Zahid et al. (22) .
The creatinine concentrations in perfusate, bath, and collected fluid were measured using a continuous flow ultramicro-colorimeter as described previously (11) . According to our previous study (11) , we waited 40 min before starting collections to washout any intrinsic vasopressin responses. Care was taken to avoid collapse of the tubule during perfusate exchanges. Experimental collections were made 10-30 min thereafter.
Urea permeability study. Urea permeability was measured as described previously ( 11, 20, 21) . In these experiments, the perfusion and bath solutions were nearly identical to the dissection solution (solution A), the only exception being that the bath solution contained 5 mM urea and no raffinose, and that the perfusate contained 5 mm raffinose and no urea. The urea concentrations in the perfusate, bath, and collected fluid were measured enzymatically using a continuous flow ultramicrofluorometer (11) .
Cyclic AMP accumulation study. Cyclic AMP is the second messenger for the V2 action of AVP. We used the isolated tubule perfusion technique to determine the luminal and basolateral effects of AVP on cAMP accumulation separately. A tIMCD was dissected in solution B without collagenase, and then cannulated at both ends. The bath solution was reduced to 100 IlI. The bath and perfusate solutions were nearly identical to dissection solution (solution B), the only exception being that both of the solutions contained 0.5 mM 3-isobutyl-1-methylxanthine (IBMX), a phosphodiesterase inhibitor. The effect of basolateral AVP was measured by adding 50 MI of prewarmed (37°C) solution B containing AVP and 0.5 mM IBMX. The effect of luminal AVP was measured by changing the perfusate to the solution B containing AVP and 0.5 mM IBMX. The bath chamber was placed on a hot plate that was warmed by circulating hot water. After 5-min incubation at 37°C, 180 ILI of 10% TCA was added to the bath to stop the reaction and to extract intracellular cAMP. All samples were transferred to 1.5-ml centrifuge tubes. 30 qI of distilled water was used to wash the bath and was then added to the samples. Each tube was centrifuged for 5 min at 3,000 rpm at 4°C. 100 Il of supernatant was stored at -20°C until the assay of cAMP. Blank samples containing medium and TCA were also stored for use as standards in each experiment.
In some studies, we examined the effects of VIa and V2 antagonists and anti-N-3 peptide on AVP-stimulated cAMP accumulation. Isolated tubule perfusion technique was not used in this study. Then, 20 al of pre-warmed AVP (final concentration of 10-9 and 10-7 M for VIa and V2 antagonists or 10-'0 M for the antibody) in the same solution was added. The reaction was terminated after 3-min incubation and cAMP was extracted by the addition of 50 I1 of ice-cold 10% TCA. 75 ql of supernatant was stored.
Determination of cAMP content was performed as described previously (10, 23) 
Results
Characterization of the antibody. When the antibody was assayed by Western blot analysis with the membrane preparation of inner medulla, it recognized a major band of 62 kD (Fig.  1) . No bands were observed after the preabsorption of the antibodies with the peptide, or using the preimmune serum. The antibodies did not recognize any bands in the membrane fraction obtained from the rat liver (data not shown). The digestion of the membrane fraction with N-glycanase resulted in a shift of molecular weight from 62 to 36 ( Fig. 1 b) , which is slightly smaller than its expected molecular weight of 40.5. In the same condition, Na-K-AtPase ,6-1 isoform was deglycosylated from 55 to 34 kD, showing that the condition was optimal (data not shown).
The antibody did not have V2 antagonistic activity. 101o°M AVP-stimulated cAMP accumulation was not different in the presence of the antisera (X500) and the preimmune serum (x500) (247.3±34.3, 157.3+18.9, and 171.0+27.1 fmol/mm per 3 min, in the presence of AVP alone, AVP plus the preimmune serum, and AVP plus anti-N-3 peptide, respectively, n = 4-8).
Immunolocalization of V2 receptor along the nephron. Intensive immunostaining was observed in the medullary and cortical thick ascending limbs (MAL and CAL, respectively), and in the cortical, outer medullary and inner medullary collecting ducts (CCD, OMCD, and IMCD, respectively) (Fig. 2, a-c) . Although all collecting ducts showed heavy staining, only some of MAL and CAL were stained (Fig. 2 b) . Proximal tubules showed no staining (Fig. 2 a) .
Among collecting ducts, deeper ones showed heavier staining with the increase of principal cells. IMCD showed heaviest staining among nephron segments. Confocal laser-scanning microscopy showed the staining not only in the basolateral membrane but also in the luminal membrane in tIMCD (Fig. 3  b) . The staining in the luminal membrane and cytoplasm was granular in tIMCD, whereas the staining in the basolateral membrane was homogeneous and heavy, suggesting that there are fewer V2 receptors in the luminal membrane. Although the luminal staining was not evident in CCD, the staining in the basolateral membrane was also less heavier than that in tIMCD (Fig. 3 a) .
Effect of luminal AVP in the absence of bath AVP. In the absence of bath AVP, luminal AVP stimulated cAMP accumulation (Fig. 4) . dD-AVP, a V2 agonist, mimicked the effect of AVP. However, the dose-response curve was shifted to the right by two logs when compared with that of bath AVP. Both luminal and basolateral oxytocin (10' M) stimulated cAMP accumulation (106.0+22.2 and 39.9±15.6 fmol/mm per 5 min, n = 4, respectively). Low pH in both the bath and luminal fluid also shifted the dose-response curve to the right.
Next, the effects of luminal AVP on Pf and Pu were examined (Fig. 5) . Time control experiments showed a decrease of Pf and Pu with time in the absence of bath and luminal AVP.
In the presence of I0-9 M AVP in the lumen, Pf and Pu were not decreased with time, suggesting a stimulatory effect of luminal AVP (Fig. 7) . The inhibition was greater in Pf than Pu.
Mechanisms of luminal AVP-induced inhibition of cAMP accumulation. Cyclic AMP is reported to be the second messenger for the V2 action of AVP. We measured cAMP accumulation in the presence of both luminal and basolateral AVP. Addition of luminal AVP decreased bath AVP-stimulated cAMP accumulation by 50% (Fig. 8) . To determine the mechanisms of luminal AVP-induced inhibition of bath AVP-stimulated cAMP accumulation, cAMP accumulation was examined in the presence of Vla and V2 antagonists, and in the presence of an oxytocin agonist and antagonist.
We first studied the effect of VIa and V2 antagonists on bath AVP-stimulated cAMP accumulation. Vla (Fig. 8) . In contrast, addition of the V2 antagonists (OPC 31260, and PTEtV-AVP) to the lumen did not alter the luminal effect of AVP. These data suggest that inhibitory effects of luminal AVP may be mediated by Vi a receptors. However, these Vi a antagonists are known to antagonize oxytocin receptors to a lesser extent. Therefore, we used a selective oxytocin antagonist and an agonist to determine if oxytocin receptors participate in the luminal action of AVP. When 10-6 M GN-OVT, a selective oxytocin antagonist (15) , was in the lumen together with AVP, the effect of luminal AVP was inhibited (Fig. 8) . A selective oxytocin agonist in the lumen, tg-OXT (13), mimicked the luminal effect of AVP on cAMP accumulation (Fig. 8) . 
Discussion
The present study shows that V2 receptor is localized in some of thick ascending limbs and all of principal and IMCD cells. There were few luminal V2 receptors as well as dense basolateral V2 receptors in the collecting ducts. The presence of V2 receptor in the luminal membrane of tIMCD was confirmed by the stimulation of cAMP accumulation, Pf, and Pu by luminal AVP in the absence of basolateral AVP. In contrast, luminal AVP inhibited the action of basolateral AVP by decreasing cAMP accumulation through Vla or oxytocin receptors and by an unknown mechanism through V2 receptors in the luminal membrane of tIMCD in the presence of basolateral AVP. Thus, AVP is thought to act from both the basolateral side and the luminal side to regulate water and urea transport in tIMCD. The predicted size of the V2 receptor from its sequence is 40 .5 kD (9) . Our immunoblot analysis showed the band of V2 receptor at 62 kD. Since we used strongly reduced conditions for SDS-PAGE, the size of V2 receptor is not overestimated. Although only one putative N-linked glycosylation site was considered from its amino acid sequences, the digestion of the membrane with N-glycanase resulted in a decrease of molecular mass from 62 to 36 kD, suggesting a large glycosylation of the receptor. The role of such a large glycosylation has to be examined further. Our immunohistochemical data of the localization of V2 receptor along the nephron are quite compatible with previous reports that used different methods (4-6, 10, 24) . Only some of CAL and MAL were stained, suggesting the heterogenious localization in thick ascending limbs. We have reported that AVP-stimulated cAMP accumulation was significantly higher in long-looped MAL than short-looped MAL (23) . The kinds of subgroups that do not have V2 receptors must be ascertained. In collecting ducts, the staining was increased in deeper ones with the increase of principal cells. The presence of luminal V2 receptor was most evident in tIMCD. Since principal cells and IMCD cells belongs almost same cell types, principal cells would have luminal V2 receptors as well as IMCD cells.
The physiological concentration of plasma AVP is -0.5
x 10-12 to 10`1 M (0.5-10 pg/ml), whereas that of urinary AVP is 10-11 to 10-9 M (25-27). Thus, the urinary concentration of AVP is 10-100 times higher than that of plasma. Since plasma concentration of AVP is relatively stable, changes in AVP concentration are much larger in urine than in plasma. receptors in the lumen may exist heavier than CCD for more complete and final regulation of water and sodium excretion.
Luminal AVP stimulated Pf and Pu in the absence of basolateral AVP, although this is not physiologic. In the physiologic condition, i.e., in the presence of basolateral AVP, luminal AVP inhibited the basolateral action of AVP. The luminal effects of AVP on Pf and cAMP accumulation were blocked by a VIa antagonist, PTMe-AVP, and by an oxytocin antagonist, GN-OVT, and mimicked by an oxytocin agonist, tg-OXT. Therefore, a part of this inhibitory effect is mediated by the decrease in basolateral AVP-stimulated cAMP accumulation by luminal AVP through the occupancy of Vla or oxytocin receptors. Teitelbaum reported that AVP and V2 receptor agonist stimulated phosphoinositide hydrolysis via occupancy of oxytocin receptors in cultured IMCD cells (29) . Han 
and colleagues
showed that high concentration ( 10 -8 M) of AVP inhibited low dose (10-' M) AVP-stimulated water permeability in IMCD through oxytocin receptor or a novel vasopressin receptor (30) . Oxytocin itself stimulated water permeability (30) . Our data of isolated perfusion study suggest the presence of VIa or oxytocin receptors in the luminal membrane of IMCD. Although luminal V2 antagonists did not inhibit the basolateral AVP-stimulated cAMP accumulation, they inhibited basolateral AVP-stimulated Pf. Thus, the occupancy of luminal V2 receptors can cause the inhibition of basolateral action of AVP by an unknown mechanism.
Receptor-ligand complexes are internalized by endocytosis (31, 32) . There are several types of receptor recycling (33, 34) . Receptors of V2 receptor in the luminal membrane is transcytosis (34) . Monometric immunoglobulin is transported from proximal small intestine (apical membrane) into the circulation (basolateral membrane). Internalization and recycling of VIa receptors have been observed in rat hepatocytes and vascular smooth muscle cells (35) (36) (37) . Internalization of V2 receptors in the basolateral membrane has also been exhibited (38) . AVP-V2 receptor complex must also be internalized from the luminal membrane. The presence of V2 receptors in the luminal membrane of tIMCD raises the possibility of transcytosis of AVP from luminal membrane to basolateral membrane or vice versa. Further studies are needed to determine the mechanisms of internalization and recycling of V2 receptor in the luminal membrane of IMCDs.
The cAMP system is controlled by the protein kinase C system. Teitelbaum 
